# Height-based equations as screening tools for high blood pressure in pediatric practice, the GENOBOX study 

Gloria Pérez-Gimeno MSC ${ }^{1}$ | Azahara I.Ruperez PhD ${ }^{1}$ | Mercedes Gil-Campos PhD ${ }^{2,3}$ | Concepción M. Aguilera PhD ${ }^{3,4,5}$ | Augusto Anguita PhD ${ }^{3,4,5}$ | Rocío Vázquez-Cobela PhD ${ }^{3,6,7,8} \mid$ Estela Skapino PhD ${ }^{1,9}$ | Luis A. Moreno PhD ${ }^{1,3}$ Rosaura Leis PhD ${ }^{3,6,7,8}$ © | Gloria Bueno-Lozano PhD ${ }^{1,3,10}$<br>${ }^{1}$ Growth Exercise, Nutrition and Development (GENUD) Research group, Universidad de Zaragoza, Instituto de Investigación Sanitartia de Aragón (IIS Aragón), Instituto Agroalimentario de Aragón-IA2 (Universidad de Zaragoza-CITA), Zaragoza, Spain<br>${ }^{2}$ Metabolic Pediatric and Investigation Unit, Reina Sofía University Hospital, Maimónides Insitute of Biomedicine Research of Córdoba (IMIBIC), University of Córdoba, Córdoba, Spain<br>${ }^{3}$ CIBEROBN, (Physiopathology of Obesity and Nutrition) Institute of Health Carlos III (ISCIII), Madrid, Spain<br>${ }^{4}$ Department of Biochemistry and Molecular Biology II, Institute of Nutrition and Food Technology "José Mataix", Center of Biomedical Research, University of Granada, Armilla, Granada, Spain<br>${ }^{5}$ Biosanitary Research Institute (IBS), University of Granada, Granada, Spain<br>${ }^{6}$ Pediatric Nutrition Research Group. Institute of Sanitary Research of Santiago de Compostela (IDIS). CHUS-USC., Santiago de Compostela, Spain<br>${ }^{7}$ Unit of Investigation in Human Nutrition, Growth and Development of Galicia (GALINUT), University of Santiago de Compostela (USC), Santiago de Compostela, Spain<br>${ }^{8}$ Unit of Pediatric Gastroenterology, Hepatology and Nutrition. Pediatric Service. University Clinical Hospital of Santiago (CHUS)., Santiago de Compostela, Spain<br>${ }^{9}$ Department of Clinical Nutrition, School of Nutrition, University of the Republic, Montevideo, Uruguay<br>${ }^{10}$ Unit of Pediatric Endocrinology, University Clinical Hospital Lozano Blesa, Zaragoza, Spain

## Correspondence

Rosaura Leis PhD, CIBEROBN, (Physiopathology of Obesity and Nutrition) Institute of Health Carlos III (ISCIII), 28029 Madrid, Spain.
Email: mariarosaura.leis@usc.es

Gloria Pérez Gimeno and Azahara I Rupérez contributed equally to this manuscript.

## Funding information

Ministerio de Ciencia e Innovación, Grant/Award Numbers: PI11/01425, PI11/02042, PI11/02059, PI16/00871, PI16/01205, PI16/01301, RD08/0072/0028, PI20/00563, PI20/00924, PI20/00988; Centro de Investigación Biomédica en Red-Fisiopatología de la Obesidad y Nutrición, Grant/Award Numbers: CB15/00043, CB15/00131


#### Abstract

Due to the absence of easily applicable cut-off points to determine high blood pressure or hypertension in children, as in the adult population, blood pressure is rarely measured in the pediatrician's clinical routine. This has led to an underdiagnosis of high blood pressure or hypertension in children. For this reason, the present study evaluate the utility of five equations for the screening of high blood pressure in children: blood pressure to height ratio, modified blood pressure to height ratio, new modified blood pressure to height ratio, new simple formula and height-based equations. The authors evaluated 1599 children between 5 and 18 years. The performance of the five equations was analyzed using the receiver-operating characteristics curves for identifying blood pressure above P90th according to the American Academy of Pediatrics Clinical Practice Guideline 2017. All equations showed an area under the curve above 0.882. The new modified blood pressure to height ratio revealed a high sensitivity whereas the height-based equations showed the best performance, with a positive predictive value above $88.2 \%$. Finally, all equations showed higher positive predictive values in


[^0]
#### Abstract

children with overweight or obesity. The height-based equation obtained the highest PPV values above $71.1 \%$ in children with normal weight and above $90.2 \%$ in children with overweight or obesity. In conclusions, the authors recommend the use of the height-based equations equation because it showed the best positive predictive values to identify children with elevated blood pressure, independently of their sex, pubertal and weight status.


## KEYWORDS

children, height-based equations, high blood pressure, pediatrician, screening

## 1 | INTRODUCTION

High blood pressure is the most important risk factor contributing to worldwide deaths. ${ }^{1,2}$ Data indicate that its prevalence has continued to rise in the recent years, ${ }^{3}$ and Europe is the region with the highest prevalence, where $55 \%$ of the adults have hypertension. ${ }^{4}$ In adults in Spain, hypertension prevalence is estimated at $42.6 \%{ }^{5}$ However, hypertension is not only present in adulthood, but also in children and adolescents. In the last two decades, hypertension has earned importance in terms of its appearance in young populations. ${ }^{6}$ One metaanalysis ${ }^{7}$ and a study done in Greece ${ }^{8}$ found a prevalence of hypertension of $16.2 \%$ among $10-19$ year-old and a $18.5 \%$ among $9-13$ year-old children, respectively.

In adults, high blood pressure stands out as one of the most important risk factors for cardiovascular diseases (CVD). ${ }^{9}$ Whereas this relationship is more difficult to establish in childhood, since cardiovascular complications usually appear over time and together with additional risk factors. ${ }^{6}$ It has been shown that hypertension tracks from childhood to adulthood. ${ }^{10-12}$ Among the developmental time frame, puberty is a key period for hypertension development. ${ }^{10}$ The development of childhood hypertension should be avoided since it is a risk factor that can cause organic damage. ${ }^{13}$

Indeed, given its early role in long-term cardiovascular risk, blood pressure needs to be monitored, even in asymptomatic children and adolescents. ${ }^{14}$ Despite its increase, ${ }^{15}$ high blood pressure it is still underdiagnosed in the pediatric routines. ${ }^{16}$ There are several reasons why hypertension may be underdiagnosed. One of these reasons could be the different cuts-off values that need to be applied in the process of diagnosis, depending on age and sex, height percentiles. ${ }^{14}$ Although there are tables based on these percentiles, some authors have proposed the use of different methods to simplify the screening of blood pressure reducing the health care visits time, ${ }^{17}$ which is usually insufficient. ${ }^{16}$

Some authors developed formulas ${ }^{18-21}$ based on simple measurements, to be used to identify hypertension defined by the 2004 Fourth report of the American of Academy of Pediatrics guidelines. ${ }^{18-21}$ However, in 2017 this guideline was updated using only children with normal weight. ${ }^{14}$ For this reason, only some authors have tested the usefulness of these formulas based on the 2017 guideline. ${ }^{22}$ While other authors have proposed new formulas adapted to the 2017
guideline. ${ }^{23,24}$ Nevertheless, no study has been found in a pediatric Spanish population using any of the mentioned formulas.

Therefore, the aim of this study was to identify the formula with the best performances to classify a sample of Spanish children and adolescents according to their blood pressure levels, based on the American Academy of Pediatrics (AAP) Clinical Practice Guideline (CPG). ${ }^{14}$

## 2 | MATERIALS AND METHODS

## 2.1 | Study sample

A sample of 1599 children and adolescents ( $48.5 \%$ males and $70.6 \%$ with overweight/obesity) participated in the GENOBOX multicenter case control study, carried out in three Spanish cities: Córdoba, Santiago de Compostela and Zaragoza. The participants and their families were informed about the aim of the study. Children were classified in two groups: cases with overweight or obesity, and controls with normal weight. The case group was recruited from children who came to the hospitals to confirm the diagnosis of overweight or obesity or for identification of minor gastrointestinal disorders that were discarded after clinical and laboratory tests. Whereas, the control group were children who came to the emergency departments owing to a common infection, that were not confirmed after laboratory tests. We included in the study children from 5 to 18 years. Those children having a chronic or inflammatory disease, a congenital disease or psychomotor disability and taking drugs for treatment of alterations in blood pressure, hormonal, glucose or lipid metabolism and those who did intensive exercise in the 24 h previous to the examination or had been involved in other studies 3 month before, were excluded from the study. The present study was approved by the Ethics Committees of each center (Code IDs: Santiago 2011/198, Zaragoza 10/2010, Córdoba 01/2017) involved in the project and was carried out following the Declaration of Helsinki principles.

## 2.2 | Anthropometric measurements

Trained researchers weighed and measured all the participants. The participants were measured in their underwear and without shoes. An
electronic scale and a stadiometer were used to measure weight and height, respectively. Then, body weight in kg was divided by the square of height in meters to obtain the body mass index (BMI). Cole and coworkers, International Obesity Task Force criteria were used to classify participants as children with normal weight or overweight/obesity according to their sex and age specific cut-offs equivalent to adult values of $25 \mathrm{~kg} / \mathrm{m}^{2}$ and $30 \mathrm{~kg} / \mathrm{m}^{2} .{ }^{25}$ Children with underweight were exclude for the study. In addition, the pubertal stage was determined according to Tannert's criteria by an expert pediatrician and confirmed with sexual hormone measurements. ${ }^{26}$ Children in Tanner stage I were considered prepubertal, and children with stages II-V were considered pubertal. Despite the participants with tanner V presented clinical signs and hormones similar to adults, they were grouped as pubertal because they still had a growth velocity around $2 \mathrm{~cm} /$ year.

## 2.3 | Blood pressure

In all participating centers, an electronic manometer (M6, HEM-7001E, Omron, Tokio, Japan), which has been approved by the British Hypertension Society, ${ }^{27}$ was used to measure systolic and diastolic blood pressure (SBP, DBP). The cuff-size was adapted to the arm circumference of each child. The blood pressure measure was taken by a trained personal in a quiet room. The child was seated on a chair with the back supported and feet undercrossed on the floor and waited 5 min until the first measurement of BP. The measures were repeated twice with a 5 min interval on the right arm and in sitting position. If the first two measures differed by more than $20 \%$ the measure was repeated a third time. Children were classified as having elevated SBP or DBP (> P90th for sex, age and height) or not, according to the AAP CPG. ${ }^{14}$ In order to avoid the risk of white coat hypertension (WCH), the BP levels of 154 of that children ( 77 with normal weight and 77 with obesity or overweight) were measured too by ambulatory blood pressure monitoring.

## 2.4 | Height-based equations

The following five height-based equations, ${ }^{18-20,23,24}$ were used to check their usefulness as tools for the detection of high blood pressure as compared with the AAP CPG ( $\geq$ P90th both systolic and diastolic). Each one of the first three equations were calculated both for SBP and DBP.
I. Blood pressure to height ratio $(\mathrm{BPHR})^{18}=\mathrm{BP} / \mathrm{Height}(\mathrm{cm})$.
II. Modified blood pressure to height ratio $(M B P H R)^{19}=B P /($ Height $(c m)+7 \times(13-$ age in years).
III. New modified blood pressure to height ratio $(\mathrm{NMBPHR})^{20}=$ $B P /($ Height $(\mathrm{cm})+3 \times(13-$ age in years $)$.
IV. New simple formula (NSF) ${ }^{23}=[1.5 \times$ systolic blood pressure + diastolic blood pressure] - [(26 $\times$ height ( m )] - age (years).
V. Elevated blood pressure cut-offs from the "Height-based equation" $(\mathrm{HBE})^{24}:$ SBP P90th $=70+0.33 \times$ height $(\mathrm{cm}) ;$ DBP P90th $=35+$ $0.25 \times$ height (cm).

## 2.5 | Statistical analyses

The sample sized estimation was calculated with a 95\% degree of confidence (type I error alpha $=0.05$ ) and a power of $80 \%$ (type II beta error $=0.20$ ) according to the estimation equation of $n$ by comparison of two proportions of one variable in two independent groups. The sample size under these conditions was raised to a total of 300 to be sure that significant differences could be found for a minimal difference of $20 \%$ in each parameter between children with obesity and normal weight. Descriptive statistics for sex, height, BMI, SBP and DBP for children and adolescents were expressed as means $\pm$ standard deviation (SD). Studentt's t-test was used to compare normally distributed variables between children of different sex and weight status. The proportion of normal SBP and DBP and those with elevated SBP and DBP were reported by frequency. Due to the observed differences between males and females, further analyses were done separated by sex.

Receiver operating characteristics curves (ROC) analyses were applied for the equations i to iv in children and adolescents with normal weight to assess their accuracy as diagnostic test for elevated SBP and DBP in the study population. The area under the curve (AUC) was used as indicator of overall ability of using i to iv and equations cut-off points to discriminate children and adolescents with elevated SBP or DBP. To assess the performance of ROC analyses we used the AUC with its 95\% confidence intervals. A perfect test will have an AUC of 1.0, and an AUC of 0.5 is equivalent to random guessing. ${ }^{28}$ From these data, the cut-off point with the highest sensitivity and specificity were selected. ${ }^{29}$ The cut-off point obtained in children with normal weight were then used to classify the total population using both systolic and diastolic cutoff points. Due to the peculiar of blood pressure diagnoses, children and adolescents are prehypertension or have elevated blood pressure when either SBP or DBP are above P90th. ${ }^{14}$ In this line new categorical variables were created unifying the presence of either elevated SBP or DBP of each equation (i to iv). For the last equation (v), no ROC analyses was needed since the formula itself gives a cut-off point to compare with each patient blood pressure level. Hence, the whole sample was classified according to have or not either SBP or DBP above or below its own cut-off point. Then, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), real prevalence and apparent prevalence and their confidence intervals, using the exact binomial statistical method, were calculated from the new categorical variable compared with the AAP CPG ( $\geq$ P90th both systolic and diastolic).

All analyses were carried out with IBM SPSS Statistics (IBM SPSS Statistics for Windows, Version 26.0. Armonk, NY, USA: IBM Corp.) and statistical significance was considered when $p<.05$.

## 3 | RESULTS

Table 1 shows their main characteristics of the participants according to age and weight status. Both boys and girls with normal weight showed significant differences with lower values in height, BMI, SBP

TA B LE 1 Descriptive characteristics of the participants including blood pressure distribution according to the American Academy of Pediatrics Clinical practice guideline 2017

| N | Normal weight |  |  |  | Overweight/Obesity |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Boys |  | Girls |  | Boys |  | Girls |  |
|  | 248 |  | $222$ |  | 528 |  | 601 |  |
|  | Median | (p25-p75) | Median | (p25-p75) | Median | (p25-p75) | Median | (p25-p75) |
| Age (years) | $9.8{ }^{\text {a }}$ | (8.2-11.5) | $10.1{ }^{\text {c }}$ | 2.5 | $10.4{ }^{\text {a }}$ | 2.4 | $10.3{ }^{\text {c }}$ | 2.6 |
| Height (m) | $1.39^{\text {a }}$ | 0.15 | $1.39{ }^{\text {c }}$ | 0.14 | $1.45{ }^{\text {b }}$ | 0.14 | $1.44{ }^{\mathrm{d}^{\text {a }}}$ | 0.14 |
| Weight (kg) | $33.5{ }^{\text {a }}$ | 11.0 | $33.5{ }^{\text {c }}$ | 10.6 | $56.3{ }^{\text {b }}$ | 18.1 | $54.7{ }^{\text {d }}$ | 17.9 |
| BMI | 17.03 ${ }^{\text {a }}$ | 2.0 | $17.22^{\text {c }}$ | 2.2 | $26.21^{\text {b }}$ | 4.4 | $25.98{ }^{\text {d }}$ | 4.6 |
| BMI-z | $-0.27^{\text {a }}$ | 0.58 | $-0.23{ }^{\text {c }}$ | 0.49 | $2.90^{\text {b }}$ | 1.54 | $2.388^{\mathrm{d}^{*}}$ | 1.25 |
| SBP (mm Hg) | $100^{\text {a }}$ | 13 | $100^{\text {c }}$ | 12 | $111^{\text {b }}$ | 14 | $110^{\text {d }}$ | 13 |
| DBP ( mm Hg ) | $60^{\text {a }}$ | 10 | $62^{\mathrm{c}^{*}}$ | 10 | $67^{\text {b }}$ | 11 | $67^{\text {d }}$ | 11 |
| SBPHR | $0.721^{\text {a }}$ | 0.10 | $0.726^{\text {c }}$ | 0.10 | $0.768^{\text {b }}$ | 0.1 | $0.770^{\text {d }}$ | 0.1 |
| DBPHR | $0.435^{\text {a }}$ | 0.07 | $0.4511^{\text {c,* }}$ | 0.08 | $0.465^{\text {b }}$ | 0.08 | $0.470^{\text {d }}$ | 0.09 |
| MSBPHR | $0.626^{\text {a }}$ | 0.09 | $0.629{ }^{\text {c }}$ | 0.08 | $0.681^{\text {b }}$ | 0.1 | $0.679^{\text {d }}$ | 0.09 |
| MDBPHR | $0.377^{\text {a }}$ | 0.06 | $0.391{ }^{\text {c }}$ * | 0.07 | $0.412^{\text {b }}$ | 0.07 | $0.414^{\text {d }}$ | 0.07 |
| NMSBPHR | $0.675^{\text {a }}$ | 0.09 | $0.679{ }^{\text {c }}$ | 0.08 | $0.726^{\text {b }}$ | 0.09 | $0.725^{\text {d }}$ | 0.08 |
| NMDBPHR | $0.407^{\text {a }}$ | 0.06 | $0.422^{\text {c,* }}$ | 0.07 | $0.439^{\text {b }}$ | 0.07 | $0.443^{\text {d }}$ | 0.07 |
| NSF | $183.2^{\text {a }}$ | 25.7 | $185.9^{\text {c }}$ | 24.5 | $206.7^{\text {b }}$ | 27.8 | $205.2^{\text {d }}$ | 25.8 |
| HBESBP | $115.8^{\text {a }}$ | 5.0 | $115.8{ }^{\text {c }}$ | 4.7 | $118.0^{\text {b }}$ | 4.6 | $117.5^{\text {d }}$ | 4.6 |
| HBE DBP | $69.7{ }^{\text {a }}$ | 3.8 | 69.7 ${ }^{\text {c }}$ | 3.6 | $71.3^{\text {b }}$ | 3.5 | 70.97 ${ }^{\text {d }}$ | 3.7 |
|  | n | (\%) | n | (\%) | n | (\%) | n | (\%) |
| Elevated SBP | 26 | 10.5 | 25 | 11.3 | 200 | 37.9 | 211 | 35.1 |
| Elevated DBP | 14 | 5.6 | 31 | 14 | 120 | 22.7 | 142 | 23.6 |

Abbreviations: BMI, Body mass index; BMI-z, Body mass index z-score; DBP, Diastolic blood pressure; DBPHR, diastolic blood pressure (BP/Height); HBE, Elevated blood pressure cut-offs from the "Height-based equation MDBPHR", Modified diastolic blood pressure to height ratio (DBP/Height+7x(13-age); MSBPHR, Modified systolic blood pressure to height ratio (SBP/Height+7x(13-age); NMSBPHR, New modified diastolic blood pressure to height ratio (DBP/Height+3x(13-age); NMSBPHR, New modified systolic blood (SBP/Height+3x(13-age); NSF, New simple formula, (1.5xSBP+DBPD)-(26xheight)-age; SBP, systolic blood pressure; SBPHR, systolic blood pressure to height ratio (BP/Height); SD, standard deviations.
*Indicates significant differences $p<0.05$ between sex in children with the same weight status. ( $a$ and $b$ ) indicates differences $p<0.050$ between boys with normal-weight versus those with overweight/obesity; ( $c$ and d) indicates differences $p<0.05$ between girls with normal-weight versus those with overweight/obesity.
and DBP than children with overweight/obesity. In addition, girls with normal weight showed significantly higher DBP values than boys with normal weight. Also, boys with overweight or obesity were significantly taller than girls with overweight or obesity. Regarding BP classification, a $29.1 \%$ of boys and $28.7 \%$ of girls showed elevated SBP. Similarly, elevated DBP was observed in $17.3 \%$ of boys and $21.0 \%$ of girls. In addition, in the subsample of 154 children the measure of BP by ambulatory blood pressure monitoring showed a $6.5 \%$ and a $13 \%$ of WCH in children with normal weight and overweight or obesity, respectively.

The performance in the identification of the optimal cut-off points for elevated BP, both in systolic and diastolic blood pressure, using the first four equations (BPHR, MBPHR, NMBPHR and NSF) is shown in Table 2. Moreover, Figure 1 shows the AUC for equations (BPHR, MPHBR and NMBPHR) compared to the AAP CPG. All equations showed an AUC with a range of 0.915-0.992 in boys. Whereas in girls the AUC range was 0.882-0.985. In addition, AUC showed better
values for boys than for girls, except in the SBPHR and NSF equations. The best AUC for the identification of elevated blood pressure was the obtained by the NMBPHR equation, both for SBP and DBP. Regarding sensitivity and specificity of cut-off points obtained, all equations showed high values (between 73.3 and 100\%). In addition, in boys all equations showed a sensitivity of $100 \%$, except BPHR for systolic blood pressure and NSF.

When participants were divided by pubertal status, the AUC range for all equations was 0.936-0.999 for prepubertal and 0.845-1.00 for pubertal children (Table S1). NMBPHR equation was found to be the best for identifying prepubertal children with elevated SBP (AUC $=0.969$ for boys and $\mathrm{AUC}=0.965$ for girls) and elevated DBP (AUC $=0.999$ for boys and AUC $=0.994$ for girls) with a sensitivity of $100 \%$, except for girls in the systolic category (95.2\%). However, in pubertal children the equation with the best AUC was BPHR, particularly SBPHR, with an AUC of 0.981 for boys and 1.00 for girls.


FIGURE 1 ROC curves for children and adolescents with normal weight, both systolic and diastolic blood pressure

In addition, BPHR for pubertal children showed an AUC with a high sensitivity (100\%), except for girls in the diastolic category (87.5\%).

Once we obtained the new categories regarding the presence or absence of elevated blood pressure according to the identified cut-offs from the studied equations, these were compared with the Gold standard classification in the whole sample. Table 3 shows sensitivity, specificity, PPV, NPV, true prevalence and apparent prevalence for the all studied equations. MBPHR showed the best sensitivity in boys (98.2\%) Whereas NSF showed the best sensitivity for girls (96.7\%). NMBPHR showed a high sensitivity both in girls and boys, (96.7\% and 95.0\%, respectively). Regarding specificity, the HBE equation showed the highest value both in boys (93.2\%) and girls (93.5\%). In addition, the HBE equation obtained the best PPV (87.5\% for boys and $88.2 \%$ for girls). As for prevalence, the true prevalence in boys was $35.2 \%$ and $36.5 \%$ in girls. BPHR, MBPHR, NMBPHR and NSF equations showed a higher apparent prevalence, and the HBE equation showed a lower apparent prevalence, than the true prevalence. The HBE equation showed the most similar apparent prevalence to the true prevalence ( $35.1 \%$ and $35 \%$ in boys and girls, respectively).

Table S2 shows the sensitivity, specificity, PPV and NPV of all height-based equations compared with AAP CPG divided by pubertal status in the all the participants. Sensitivity values were between 80.4 and $97.4 \%$ in children with prepubertal status and between 59.5 and $95 \%$ in children with pubertal status. Similarly, specificity range was 73.9-91.2\% and 79.3-97.8\% in children with prepubertal and
pubertal status, respectively. Respect PPV the HBE equation showed the highest values in prepubertal and pubertal children.

Finally, Table 4 shows the sensitivity, specificity, PPV, NPV, real prevalence and apparent prevalence when the analysis was stratified by BMI status. Participants with higher BMI showed higher PPV than those with normal BMI. Both in children with normal weight and children with overweight or obesity the HBE equations obtained the best PPV (71.1 and 71.4\% for boys and girls with normal weight, respectively; and 90.2 and $91.6 \%$ for boys and girls with overweight or obesity).

## 4 | DISCUSSION

The present study shows the usefulness of different height-based equations for the detection of elevated blood pressure in Spanish children. All equations ( $i$ to iv ) were found to be useful for the identification of elevated blood pressure (AUC above 0.882). However, some of them revealed better results than others. This is the case for the HBE equation, ${ }^{24}$ which showed the best PPV in the identification of children with blood pressure above the P90th both in children with normal weight and children with overweight or obesity. On the other hand, the NMBPHR equation turned out to be the best equation for the identification of children with blood pressure above the P90th (with the highest AUC and sensitivity).
TABLE 2 Identification of the optimal cut-off points in children with normal weight using four height-based equations, according to systolic and diastolic blood pressure

 of Systolic and Diastolic respectively; NSF, New Simple Formula.
Sensitivity and specificity were computed for their corresponding optimal cutoff points independently for SBP and DBP in the different equations.
Reference according to the American Academy of Pediatrics Clinical practice guideline 2017 as the gold standard ( $\geq$ P90th both systolic and diastolic blood pressure)

Due to the high number of cut-off points that have to be considered in the diagnosis of hypertension using the AAP CPG, and the time needed to search for the appropriate cut-off point of each child, some authors have developed simple tools to facilitate the correct classification of children according to the their blood pressure levels. ${ }^{18-20,23,24}$ Using the AAP CPG, Zhang and coworkers, ${ }^{30}$ found that the NMBPHR equation had a better performance in the identification of high blood pressure (above P95th) compared with the BPHR and MBPHR equations, in American children. However, the MBPHR was the equation with the best performance in Chinese children. ${ }^{30}$ Similarly, Yazdi and coworkers observed that the NMBPHR equation had a better performance than the BPHR and MBPHR equations in the identification of high blood pressure in Iranian children ( $7-12$ years). ${ }^{31}$ In our study, among the equations used in that studies, the NMNPHR was the best for the identification of elevated blood pressure in Spanish children. Compared with the studies of Zhang and Yazdi, ${ }^{30,31}$ we obtained a moderately higher PPV. In a study similar to ours, Mourato and coworkers ${ }^{32}$ in American and Brazilian children, observed NMBPHR as the equation with the best performance. Thus, our study seems to confirm the best results for the NMBPHR equation. In addition, these results were observed with similar cut-off points to those obtained in previous studies. ${ }^{22,30,31}$

Di Bonito and coworkers ${ }^{23}$ created the NSF based on the 2017 AAP CPG especially for children with overweight or obesity and obtained a good PPV (84-83\%). ${ }^{23}$ In our study, although we found a lower PPV both in boys and girls, when data were analyzed by weight status, the analysis in children with overweight or obesity showed an increase in PPV compared to children with normal weight (69.4-69.1\% vs. 50.861.9\%).

The HBE is the most practical equation because it showed the best performance and it does not require age to be introduced in the calculation. It is very useful in clinical practice where the pediatricians can measure blood pressure and classify children accordingly. If the blood pressure levels (SBP and DBP) are above the data obtained with the HBE, it indicates that children have elevated blood pressure. ${ }^{24}$ In a recent study performed in South America, the HBE was the equation with the best performance to identify elevated blood pressure (> P90th, according to the AAP CPG), showing also a high sensitivity, NPV and a PPV above 53.8, with male children and adolescents showing the maximum PPV values ( 72.6 and 63.2, respectively). ${ }^{22}$

It is well known that children with overweight or obesity have higher prevalence of hypertension than children with normal weight. ${ }^{33}$ For this reason, when other studies studied the performance of the different equations according to weight status, the subgroups with overweight or obesity showed better PPV. ${ }^{30,31}$ In our study, when the analyses were stratified by weight status we found higher PPV in children with overweight or obesity than in children with normal weight. In children with normal weight we obtained the higher PPV in the HBE equation ( $71.1 \%$ and $71.4 \%$, in boys and girls, respectively). Whereas in children with overweight or obesity the PPV increased until (90.2\% and $91.6 \%$, in boys and girls, respectively). This suggests that although children with normal weight obtained a high PPV percentage in the HBE
TAB LE 3 Performance of all height-based equations in the whole sample using the cut-off points obtained in participants with normal weight, considering the American Academy of Pediatrics Clinical practice guideline 2017 diagnosis as the gold standard ( $\geq$ P90th both systolic and diastolic blood pressure)

|  | BPHR |  | MBPHR |  | NMBPHR |  | NSF |  | HBE* |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Boys | Girls | Boys | Girls | Boys | Girls | Boys | Girls | Boys | Girls |
| n | 776 | 823 | 776 | 823 | 776 | 823 | 776 | 823 | 776 | 823 |
| Cut-off points | 0.805 | 0.788 | 0.659 | 0.679 | 0.732 | 0.738 | 200.29 | 200.1 | N/A | N/A |
|  | /0.505 | /0.523 | /0.422 | /0.418 | /0.485 | /0.474 |  |  |  |  |
| Sensitivity\% (95\% CI) | $\begin{aligned} & 80.2 \\ & (75.0-84.8 \%) \end{aligned}$ | $\begin{aligned} & 85.3 \\ & \quad(80.8-89.1 \%) \end{aligned}$ | $\begin{aligned} & 98.2 \\ & (95.8-99.4 \%) \end{aligned}$ | $\begin{aligned} & 92.0 \\ & (88.3-94.8 \%) \end{aligned}$ | $\begin{aligned} & 96.7 \\ & \quad(93.8-98.5 \%) \end{aligned}$ | $\begin{aligned} & 95.0 \\ & (91.9-97.2 \%) \end{aligned}$ | $\begin{aligned} & 92.3 \\ & (88.5-95.2 \%) \end{aligned}$ | $\begin{aligned} & 96.7 \\ & \quad(94-98.4 \%) \end{aligned}$ | $\begin{aligned} & 87.2 \\ & (82.6-90.9 \%) \end{aligned}$ | $\begin{aligned} & 84.7 \\ & \text { (80.1-88.6\%) } \end{aligned}$ |
| Specificity\% (95\% CI) | $\begin{aligned} & 86.3 \\ & \quad(83.0-89,2 \%) \end{aligned}$ | $\begin{aligned} & 84.9 \\ & (81.5-87.9 \%) \end{aligned}$ | $\begin{aligned} & 61.4 \\ & (57.0-65.7 \%) \end{aligned}$ | $\begin{aligned} & 66.5 \\ & \quad(62.3-70.6 \%) \end{aligned}$ | $\begin{aligned} & 81.3 \\ & (77.6-84.6 \%) \end{aligned}$ | $\begin{aligned} & 84.7 \\ & \quad(81.3-87.7 \%) \end{aligned}$ | $\begin{aligned} & 74.8 \\ & (70.7-78.5 \%) \end{aligned}$ | $\begin{aligned} & 74.0 \\ & \quad(70.0-77.7 \%) \end{aligned}$ | $\begin{aligned} & 93.2 \\ & (90.7-95.3 \%) \end{aligned}$ | $\begin{aligned} & 93.5 \\ & \quad(91-95.5 \%) \end{aligned}$ |
| PPV\% (95\% CI) | $\begin{aligned} & 76.0 \\ & (70.7-80.9 \%) \end{aligned}$ | $\begin{aligned} & 76.4 \\ & (71.5-80.9 \%) \end{aligned}$ | $\begin{aligned} & 58.0 \\ & \quad(53.4-62.6 \%) \end{aligned}$ | $\begin{aligned} & 61.2 \\ & (56.5-65.7 \%) \end{aligned}$ | $\begin{aligned} & 73.7 \\ & \quad(68.9-78.2 \%) \end{aligned}$ | $\begin{aligned} & 78.1 \\ & \quad(73.5-82.2 \%) \end{aligned}$ | $\begin{aligned} & 66.5 \\ & (61.5-71.2 \%) \end{aligned}$ | 68.1 (63.4-72.5\%) | $\begin{aligned} & 87.5 \\ & \quad(83.0-91.2 \%) \end{aligned}$ | 88.2 (83.9-91.7\%) |
| NPV\% (95\% CI) | $\begin{aligned} & 89.0 \\ & (85.8-91.6 \%) \end{aligned}$ | $\begin{aligned} & 91.0 \\ & \quad(88.1-93.4 \%) \end{aligned}$ | 98.4 <br> (96.3-99.5\%) | $\begin{aligned} & 93.5 \\ & \quad \text { (90.6-95.8\%) } \end{aligned}$ | $\begin{aligned} & 97.8 \\ & \quad(96.0-99.0 \%) \end{aligned}$ | $\begin{aligned} & 96.7 \\ & \quad(94.7-98.2 \%) \end{aligned}$ | $\begin{aligned} & 94.7 \\ & \quad(92-96.7 \%) \end{aligned}$ | $\begin{aligned} & 97.5 \\ & \quad \text { (95.4-98.8\%) } \end{aligned}$ | $\begin{aligned} & 93.1 \\ & \quad(90.5-95.1 \%) \end{aligned}$ | $\begin{aligned} & 91.4 \\ & (88.7-93.6 \%) \end{aligned}$ |
| True prevalence\% (95\% CI) | $\begin{aligned} & 35.2 \\ & (31.8-28.7 \%) \end{aligned}$ | $\begin{aligned} & 36.5 \\ & \quad(33.2-39.8 \%) \end{aligned}$ | $\begin{aligned} & 35.2 \\ & (31.8-38.7 \%) \end{aligned}$ | $\begin{aligned} & 36.5 \\ & (33.2-39.8 \%) \end{aligned}$ | $\begin{aligned} & 35.2 \\ & (31.8-38.7) \end{aligned}$ | $\begin{aligned} & 36.5 \\ & \quad(33.2-39.8 \%) \end{aligned}$ | $\begin{aligned} & 35.2 \\ & (31.8-38.7 \%) \end{aligned}$ | $\begin{aligned} & 36.5 \\ & \quad(33.2-39.8 \%) \end{aligned}$ | $\begin{aligned} & 35.2 \\ & (31.8-38.7 \%) \end{aligned}$ | $\begin{aligned} & 36.5 \\ & (33.2-39.8 \%) \end{aligned}$ |
| Apparent prevalence\% (95\% <br> $\mathrm{Cl})$ | $\begin{aligned} & 37.1 \\ & (33.7-40.6 \%) \end{aligned}$ | $\begin{aligned} & 40.7 \\ & (37.3-44.4 \%) \end{aligned}$ | $\begin{aligned} & 59.5 \\ & (56.0-63.0 \%) \end{aligned}$ | $\begin{aligned} & 54.8 \\ & (51.3-58.2 \%) \end{aligned}$ | $\begin{aligned} & 46.1 \\ & (42.6-49.7 \%) \end{aligned}$ | $\begin{aligned} & 44.3 \\ & \quad(40.9-46.8 \%) \end{aligned}$ | $\begin{aligned} & 48.8 \\ & (45.3-52.4 \%) \end{aligned}$ | $\begin{aligned} & 51.8 \\ & \quad(48.3-55.2 \%) \end{aligned}$ | $\begin{aligned} & 35.1 \\ & (31.7-38.5 \%) \end{aligned}$ | $\begin{aligned} & 35.0 \\ & (31.7-38 . \%) \end{aligned}$ |

 NMBPHR, New MBPHR; NSF, New simple formula.
 2017.

* HBE cut-off points are not available due to the special characteristics of the HBE equation mentioned in the methodology section.
TABLE 4 Performance of all height-based equations in the whole sample divided by weight status, using the cut-off points obtained in participants with normal weight

| Normal weight n | BPHR |  | MBPHR |  | NMBPHR |  | NSF |  | HBE* |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Boys | Girls | Boys | Girls | Boys | Girls | Boys | Girls | Boys | Girls |
|  | 248 | 222 | 248 | 222 | 248 | 222 | 248 | 222 | 248 | 222 |
| Sensitivity\% (95\% <br> $\mathrm{Cl})$ | $\begin{aligned} & 94.1 \\ & \text { (80.3-99.3\%) } \end{aligned}$ | $\begin{aligned} & 90.7 \\ & (77.9-97.4 \%) \end{aligned}$ | $\begin{aligned} & 100 \\ & \text { (89.7-100\%) } \end{aligned}$ | $\begin{aligned} & 95.3 \\ & \text { (84.2-99.4\%) } \end{aligned}$ | $\begin{aligned} & 100 \\ & \quad(89.7-100 \%) \end{aligned}$ | $\begin{aligned} & 93.0 \\ & \quad(80.9-98.5 \%) \end{aligned}$ | $\begin{aligned} & 88.2 \\ & \quad(72.6-96.7 \%) \end{aligned}$ | $\begin{aligned} & 90.7 \\ & \quad(77.9-97.4 \%) \end{aligned}$ | $\begin{aligned} & 79.4 \\ & \quad(62.1-91.3 \%) \end{aligned}$ | $\begin{aligned} & 81.4 \\ & \quad(66.6-91.6 \%) \end{aligned}$ |
| Specificity\% (95\% $\mathrm{Cl})$ | $\begin{aligned} & 84.6 \\ & (79.0-89.1 \%) \end{aligned}$ | $\begin{aligned} & 89.0 \\ & \text { (84.6-93.9\%) } \end{aligned}$ | $\begin{aligned} & 69.2 \\ & (62.5-75.3 \%) \end{aligned}$ | $\begin{aligned} & 69.8 \\ & (62.5-76.5 \%) \end{aligned}$ | $\begin{aligned} & 83.2 \\ & (77.5-87.9 \%) \end{aligned}$ | $\begin{aligned} & 87.2 \\ & \quad(81.4-91.7 \%) \end{aligned}$ | $\begin{aligned} & 86.4 \\ & \quad(81.1-90.7 \%) \end{aligned}$ | $\begin{aligned} & 86.6 \\ & \text { (80.7-91.2\%) } \end{aligned}$ | $\begin{aligned} & 94.9 \\ & \quad(91-97.4 \%) \end{aligned}$ | $\begin{aligned} & 92.2 \\ & \quad(87.2-95.7 \%) \end{aligned}$ |
| PPV\% (95\% CI) | $\begin{aligned} & 49.2 \\ & (36.6-62.9 \%) \end{aligned}$ | $\begin{aligned} & 68.4 \\ & \quad(54.8-80.1 \%) \end{aligned}$ | $\begin{aligned} & 34 \\ & (24.8-44.2 \%) \end{aligned}$ | $\begin{aligned} & 43.2 \\ & (33.0-53.7 \%) \end{aligned}$ | $\begin{aligned} & 48.6 \\ & \quad(36.4-60.8 \%) \end{aligned}$ | $\begin{aligned} & 63.5 \\ & \quad(50.4-75.3 \%) \end{aligned}$ | $\begin{aligned} & 50.8 \\ & \quad(37.5-64.1 \%) \end{aligned}$ | $\begin{aligned} & 61.9 \\ & (48.8-73.9 \%) \end{aligned}$ | $\begin{aligned} & 71.1 \\ & \quad(54.1-84.6 \%) \end{aligned}$ | $\begin{aligned} & 71.4 \\ & (56.7-83.4 \%) \end{aligned}$ |
| NPV\% (95\% CI) | $\begin{aligned} & 98.9 \\ & \quad(97.4-100 \%) \end{aligned}$ | $\begin{aligned} & 97.6 \\ & \quad(93.9-99.3 \%) \end{aligned}$ | $\begin{aligned} & 100 \\ & (97.5-100 \%) \end{aligned}$ | $98.4$ <br> (94.4-99.8\%) | $\begin{aligned} & 100 \\ & (98-100 \%) \end{aligned}$ | 98.1 <br> (94.6-99.6\%) | $\begin{aligned} & 97.9 \\ & (94.7-99.4 \%) \end{aligned}$ | $\begin{aligned} & 97.5 \\ & (93.7-99.3 \%) \end{aligned}$ | $\begin{aligned} & 96.7 \\ & \quad(93.3-98.7 \%) \end{aligned}$ | $\begin{aligned} & 95.4 \\ & \quad \text { (91.1-98.0\%) } \end{aligned}$ |
| True prevalence\% ( $95 \% \mathrm{CI}$ ) | $\begin{aligned} & 13.7 \\ & \quad \text { (9.7-18.6\%) } \end{aligned}$ | $19.4$ <br> (14.4-25.2\%) | $\begin{aligned} & 13.7 \\ & \quad(9.7-18.6 \%) \end{aligned}$ | $19.4$ <br> (14.4-25.2\%) | $\begin{aligned} & 13.7 \\ & \quad(9.7-18.6 \%) \end{aligned}$ | $19.4$ <br> (14.4-25.2\%) | $\begin{aligned} & 13.7 \\ & \quad(9.7-18.6 \%) \end{aligned}$ | $19.4$ <br> (14.4-25.2\%) | $\begin{aligned} & 13.7 \\ & \quad(9.7-18.6 \%) \end{aligned}$ | $19.4$ <br> (14.4-25.2\%) |
| Apparent prevalence\% (95\% CI) | $\begin{aligned} & 26.2 \\ & \quad(20.9-32.2 \%) \end{aligned}$ | $\begin{aligned} & 25.7 \\ & \quad(20.1-32.0 \%) \end{aligned}$ | $\begin{aligned} & 40.3 \\ & (34.2-46.7 \%) \end{aligned}$ | $\begin{aligned} & 42.8 \\ & \quad(36.2-49.6 \%) \end{aligned}$ | $\begin{aligned} & 28.2 \\ & \quad(22.7-34.3 \%) \end{aligned}$ | $\begin{aligned} & 28.4 \\ & \quad(22.6-34.8 \%) \end{aligned}$ | $\begin{aligned} & 23.5 \\ & \quad(18.6-29.6 \%) \end{aligned}$ | $\begin{aligned} & 28.4 \\ & \quad(22.6-34-8 \%) \end{aligned}$ | $\begin{aligned} & 15.3 \\ & (11.1-20.4 \%) \end{aligned}$ | $\begin{aligned} & 22.1 \\ & \quad(16.8-28.1 \%) \end{aligned}$ |
| Overweight and Obesity |  |  |  |  |  |  |  |  |  |  |
| $n$ | 528 | 601 | 528 | 601 | 528 | 601 | 528 | 601 | 528 | 601 |
| Sensitivity\% (95\% Cl ) | $\begin{aligned} & 78.2 \\ & \quad(72.5-83.3 \%) \end{aligned}$ | $\begin{aligned} & 84.4 \\ & (79.4-88.6 \%) \end{aligned}$ | $\begin{aligned} & 97.9 \\ & (95.2-99.3 \%) \end{aligned}$ | $\begin{aligned} & 91.4 \\ & (87.3-94.6 \%) \end{aligned}$ | $\begin{aligned} & 96.2 \\ & \quad(93.0-98.3 \%) \end{aligned}$ | $\begin{aligned} & 95.3 \\ & (92.0-97.6 \%) \end{aligned}$ | $\begin{aligned} & 92.9 \\ & \quad(88.9-95.8 \%) \end{aligned}$ | $\begin{aligned} & 97.7 \\ & \quad(95.0-99.1 \%) \end{aligned}$ | $\begin{aligned} & 88.3 \\ & \quad(83.5-92.1 \%) \end{aligned}$ | $\begin{aligned} & 85.2 \\ & \quad(80.3-89.3 \%) \end{aligned}$ |
| Specificity\% (95\% <br> $\mathrm{Cl})$ | $\begin{aligned} & 87.5 \\ & \quad(83.2-91.1 \%) \end{aligned}$ | $82.3$ <br> (77.8-86.2\%) | $55.7$ <br> (49.8-61.5\%) | $\begin{aligned} & 64.8 \\ & \quad(59.5-69.9 \%) \end{aligned}$ | $\begin{aligned} & 79.9 \\ & (74.8-84.45) \end{aligned}$ | $83.4$ <br> (79.1-87.2\%) | $66.1$ (60.3-71.5\%) | $\begin{aligned} & 67.4 \\ & \quad(62.2-72.4 \%) \end{aligned}$ | $\begin{aligned} & 92.0 \\ & \quad(88.3-94.9 \%) \end{aligned}$ | $\begin{aligned} & 94.2 \\ & (91.2-96.4 \%) \end{aligned}$ |
| PPV\% (95\% CI) | $83.9$ <br> (78.4-88.4\%) | $\begin{aligned} & 78.1 \\ & (72.7-82.8 \%) \end{aligned}$ | $\begin{aligned} & 64.6 \\ & \quad(59.5-69.6 \%) \end{aligned}$ | $\begin{aligned} & 66.0 \\ & (60.8-70.9 \%) \end{aligned}$ | $\begin{aligned} & 79.9 \\ & (74.8-84.3 \%) \end{aligned}$ | $\begin{aligned} & 81.1 \\ & \text { (76.3-85.4\%) } \end{aligned}$ | $\begin{aligned} & 69.4 \\ & \quad(64.0-74.4 \%) \end{aligned}$ | $\begin{aligned} & 69.1 \\ & \quad(64.1-73.9 \%) \end{aligned}$ | $\begin{aligned} & 90.2 \\ & (85.6-93.7 \%) \end{aligned}$ | $\begin{aligned} & 91.6 \\ & (87.4-92.5 \%) \end{aligned}$ |
| NPV\% (95\% CI) | $\begin{aligned} & 83.0 \\ & (78.3-87.0 \%) \end{aligned}$ | $\begin{aligned} & 87.6 \\ & (83.5-91.0 \%) \end{aligned}$ | $\begin{aligned} & 97.0 \\ & (93.1-99.0 \%) \end{aligned}$ | $\begin{aligned} & 91.0 \\ & (86.7-94.3 \%) \end{aligned}$ | $\begin{aligned} & 96.3 \\ & \quad(93.0-98.3 \%) \end{aligned}$ | $\begin{aligned} & 96.0 \\ & \quad(93.1-97.0 \%) \end{aligned}$ | $\begin{aligned} & 91.8 \\ & (87.2-95.2 \%) \end{aligned}$ | $\begin{aligned} & 97.5 \\ & (94.6-99.1 \%) \end{aligned}$ | $\begin{aligned} & 90.5 \\ & \quad(86.5-93.6 \%) \end{aligned}$ | $\begin{aligned} & 89.5 \\ & \quad(85.9-92.5 \%) \end{aligned}$ |
| True prevalence\% (95\% CI) | $\begin{aligned} & 45.3 \\ & (41.0-49.6 \%) \end{aligned}$ | $\begin{aligned} & 42.8 \\ & (38.8-46.8 \%) \end{aligned}$ | $\begin{aligned} & 45.3 \\ & (41.0-49.6 \%) \end{aligned}$ | $\begin{aligned} & 42.8 \\ & (38.8-46.8 \%) \end{aligned}$ | $\begin{aligned} & 45.3 \\ & \quad(41.0-49.6 \%) \end{aligned}$ | $\begin{aligned} & 42.8 \\ & (38.8-46.8 \%) \end{aligned}$ | $\begin{aligned} & 45.3 \\ & (41.0-49.6 \%) \end{aligned}$ | $\begin{aligned} & 42.8 \\ & (38.8-64.3 \%) \end{aligned}$ | $\begin{aligned} & 45.3 \\ & \quad(41.0-49.6 \%) \end{aligned}$ | $\begin{aligned} & 42.8 \\ & \quad(38.8-46.8 \%) \end{aligned}$ |
| Apparent prevalence\% (95\% CI) | $\begin{aligned} & 42.2 \\ & \quad(38.0-46.6 \%) \end{aligned}$ | $\begin{aligned} & 46.3 \\ & (42.2-50.3 \%) \end{aligned}$ | $\begin{aligned} & 68.6 \\ & \quad(64.4-72.5 \%) \end{aligned}$ | $\begin{aligned} & 59.2 \\ & \quad(55.2-63.2 \%) \end{aligned}$ | $\begin{aligned} & 54.5 \\ & \quad(50.2-58.9 \%) \end{aligned}$ | $\begin{aligned} & 50.2 \\ & \quad(46.2-54.3 \%) \end{aligned}$ | $\begin{aligned} & 60.6 \\ & \quad(56.3-64.8 \%) \end{aligned}$ | $\begin{aligned} & 60.4 \\ & \quad(56.4-64.3 \%) \end{aligned}$ | $\begin{aligned} & 44.3 \\ & (40.0-48.7 \%) \end{aligned}$ | $\begin{aligned} & 39.8 \\ & (35.8-43.8 \%) \end{aligned}$ |

Abbreviation: AUC Area Under the Curve, PPV Positive Predictive Value, NPV Negative Predictive Value, BPHR Blood Pressure to Height Ratio, CI confidence interval, HBE Height-Based Equation, MBPHR Modified BPHR, NMBPHR: New MBPHR, NSF: New simple formula.
ROC analyses were performed to evaluate the usefulness of the cutoffs obtained from the different height-based equations to diagnose elevated BP according to the American Academy of Pediatrics Clinical practice guideline 2017.
*HBE cut-off points are not available due to the special characteristics of the HBE equation mentioned in the methodology section. Considering the American Academy of Pediatrics Clinical practice guideline 2017 diagnosis as the gold standard
equation, this percentage was higher when compared with their counterparts with overweight/obesity.

To our knowledge, this is the first study to assess the performance of different height-based equations to identify children and adolescents with elevated blood pressure in Spain. Others studies have done the analyses with other populations (American, Sud-American, Chinese). It should be noted the importance of puberty since it is a factor to be asses in childhood. And it is the first study of this type in which puberty has been taken into account. For these reason these cut-off points obtained in Spanish children and adolescents could be used as a reference for Spanish population in order to screening children or adolescents with elevated blood pressure. Moreover, the study was performed in a large sample and considering three different subgroups for the analyses (sex, weight status and pubertal status). The results obtained in children with normal weight have been confirmed in the children and adolescents with higher risk of hypertension (children and adolescents with overweight or obesity). Also, the cut-off points were identified only in children with normal weight, following the AAP CPG recommendation, which may explain the better AUC obtained in the children with normal weight when compared with those with overweight/obesity.

However, the study has several limitations. First, the use of an oscillometric device instead of a mercury sphygmomanometer. Although the oscillometric device was validated and its use is recommended by the AAP CPG, most previous studies used a mercury sphygmomanometer as it is the most accurate method. The oscillometric device was the selected method to measure blood pressure because it does not need prior preparation and its measurements are reproducible in other contexts such as schools. So, its use in other settings could be adequate to detect children with elevated blood pressure. Second, blood pressure level was measured at one visit instead of three visits as recommended by the AAP CPG. One of the risks of performing a single auscultation visit is the masking of white coat hypertension, specifically in the group of children with hypertension. Taking into account this, a small subsample was measured by ambulatory blood pressure monitoring too and the percentage of WCH found was low compared with other studies. ${ }^{34,35}$ Third, the terminal digit preference in the measure of BP levels, specifically in SBP, was zero. However, a recent study has shown how the use of automated devices decrease the percentage of BP recordings ending in zero. Although zero is still the terminal digit preference with the highest prevalence in the BP records. ${ }^{36}$

In conclusions, the HBE equation showed the best PPV to identify children with elevated blood pressure, independently of their sex and pubertal weight status. The HBE is a simple formula and it could be included in the pediatrician's clinical routine or in other public health activities.

## ACKNOWLEDGMENTS

The authors would like to thank the children and their parents for their participation in the study. Funded by the Ministry for Science and Innovation (GENOBOX PI11/01425, PI11/02042, PI11/02059; PUBMEP PI16/00871, PI16/01301, PI16/01205) and IBEROMICS PI20/00563, PI20/00924, PI20/00988 SAMID (RD08/0072/0028) and CIBEROBN
(CB15/00131, CB15/00043) networks. GPG was funded by a predoctoral fellowship from the Government of Aragón.

## AUTHOR CONTRIBUTIONS

Conceptualization, Mercedes Gil-Campos, Rosaura Leis, Concepción M. Aguilera, Luis A. Moreno and Gloria Bueno-Lozano; methodology, Gloria Pérez-Gimeno, Azahara I. Ruperez, Mercedes Gil-Campos, Estela Skapino, Rosaura Leis, Concepción M. Aguilera, Luis A. Moreno and Gloria Bueno-Lozano; patient recruitment, Rocío Vázquez-Cobela, Mercedes Gil-Campos, Rosaura Leis, Gloria Bueno-Lozano; biochemical analyses: Concepción M. Aguilera, Augusto Anguita; data curation, Gloria Pérez-Gimeno, Azahara I. Ruperez, Estela Skapino, Augusto Anguita; writing original draft preparation, Gloria Pérez-Gimeno, Azahara I. Ruperez, Luis A. Moreno, Rosaura Leis, Gloria Bueno-Lozano; writing-review and editing, all authors.; funding acquisition, Mercedes Gil-Campos, Rosaura Leis, Concepción M. Aguilera, Luis A. Moreno and Gloria Bueno-Lozano.

## CONFLICT OF INTEREST

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

## ORCID

Rosaura Leis PhD (ID https://orcid.org/0000-0002-0540-4210

## REFERENCES

1. Forouzanfar MH, Liu P, Roth GA, et al. Global burden of hypertension and systolic blood pressure of at least 110 to $115 \mathrm{~mm} \mathrm{Hg}, 1990-2015$. JAMA. 2017;317(2):165-182.
2. GBD 2016 Risk Factors Collaboratos. Global, Regional, and National comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet.2017;390(10100):1345-1422.
3. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19.1 million participants. Lancet. 2017;389(10064):37-55.
4. Beaney T, Schutte AE, Tomaszewski M, et al. May Measurement Month 2017: an analysis of blood pressure screening results worldwide. Lancet Glob Health. 2018;6(7):e736-e743.
5. Menéndez E, Delgado E, Fernández-Vega F, et al. Prevalence, diagnosis, treatment, and control of hypertension in Spain. Results of the Di@bet.es study. Rev Esp Cardiol (English ed). 2016;69(6):572-578.
6. Lurbe E. Examining hypertension in children and adolescents: clinical implications of the differences between the European and American Guidelines. An Pediatr (Engl Ed). 2018;89(4):255.e1-255.e5.
7. De Moraes ACF, Lacerda MB, Moreno LA, Horta BL, Carvalho HB. Prevalence of high blood pressure in 122,053 adolescents: a systematic review and meta-regression. Medicine. 2014;93(27):e232.
8. Karatzi K, Protogerou AD, Moschonis G, Tsirimiagou C, Androutsos O, Chrousos GP, Lionis C, Manios YPrevalence of hypertension and hypertension phenotypes by age and gender among schoolchildren in Greece: The healthy growth study. Atherosclerosis. 2017; 259:128133.
9. McGill H, McMahan C, Gidding S. Preventing heart disease in the 21st century: implications of the Pathobiological Determinants of

Atherosclerosis in Youth (PDAY) Study. Circulation.2008;117(9):12161227.
10. Shen W, Zhang T, Li S, Zhang H, Xi Bo, Shen H, Fernandez C, Bazzano L, He J, Chen W.Race and sex differences of long-term blood pressure profiles from childhood and adult hypertension: the bogalusa heart study. Hypertension. 2017;70(1):66-74.
11. Chen X , Wang Y. Tracking of blood pressure from childhood to adulthood: a systematic review and meta-regression analysis. Circulation 2008;117(25):3171-3180.
12. Hao G, Wang X, Treiber FA, Harshfield G, Kapuku G, Su S. Blood Pressure Trajectories From Childhood to Young Adulthood Associated With Cardiovascular Risk: Results From the 23-Year Longitudinal Georgia Stress and Heart Study. Hypertension. 2017;69(3):435-442.
13. Litwin M, Niemirska A, Śladowska-Kozlowska J, Wierzbicka A, Janas R, Wawer ZT, Wisniewski A, Feber JRegression of target organ damage in children and adolescents with primary hypertension. Pediatr Nephrol 2010;25(2):2489-2499
14. Flynn JT, Kaelber DC, Baker-Smith CM, Blowey D, Carroll AE, Daniels SR, De Ferranti SD, Dionne JM, Falkner B, Flinn SK, Gidding SS, Goodwin C, Leu MG, Powers ME, Rea C, Samuels J, Simasek M, Thaker VV, Urbina EMClinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. Pediatrics 2017;140(3):e20171904.
15. Sabri M, Gheissari A, Mansourian M, Mohammadifard N, Sarrafzadegan N. Essential hypertension in children, a growing worldwide problem. J Res Med Sci. 2019; 24:109.
16. Hansen ML, Gunn PW, Kaelber DC. Underdiagnosis of Hypertension in Children and Adolescents. JAMA. 2007;298(8):874-879.
17. Ma C, Wang R, Liu Y, Lu Q, Lu Na, Tian Y, Liu X, Yin FPerformance of User-Friendly Screening Tools for Elevated Blood Pressure in Children Pediatrics. 2017; 139(2):e20161986.
18. Lu Q, Ma CM, Yin FZ, Liu BW, Lou DH, Liu XL. How to simplify the diagnostic criteria of hypertension in adolescents. J Hum Hypertens, 2011;25(3):159-163.
19. Mourato FA, Nadruz W, Moser LRDN, De Lima Filho JL, Mattos SS. A modified blood pressure to height ratio improves accuracy for hypertension in childhood. Am J Hypertens. 2015;28(3):409-413.
20. Ma C, Lu Q, Wang R, Liu X, Lou D, Yin F. A new modified blood pressure-to-height ratio simplifies the screening of hypertension in Han Chinese children. Hypertens Res. 2016;39(12):893-898.
21. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114(2):555-576.
22. Skapino E, Rupérez AI, Restrepo-Mesa S, Araújo-Moura K, De Moraes AC, Barbosa Carvalho H, Aristizabal JC, Moreno LAHeight-based equations as screening tools for elevated blood pressure in the SAYCARE study. J Clin Hypertens (Greenwich). 2020;22(12):22212229.
23. Di Bonito P, Licenziati MR, Di Sessa A, Manco M, Morandi A, Maffeis C, Chiesa C, Pacifico L, Valerio GA new simple formula built on the Amer ican Academy of Pediatrics criteria for the screening of hypertension in overweight/obese children. Eur J Pediatr. 2019; 178(8):1291-1295.
24. Mourato FA, Mattos SS, Lima Filho JL, Mourato MF, Nadruz W. HeightBased Equations Can Improve the Diagnosis of Elevated Blood Pressure in Children. Am J Hypertens. 2018;31(9):1059-1065.
25. Cole TJ, Lobstein T. Extended international (IOTF) body mass index cut-offs for thinness, overweight and obesity. Pediatr Obes. 2012;7(4):284-294.
26. Bornstein MH. Tanner Stages. In The SAGE Encyclopedia of Lifespan Human Development; SAGE Publications, In: Thousand Oaks, CA, USA 2018.
27. Topouchian JA, El Assaad MA, Orobinskaia LV, El Feghali RN, Asmar RG. Validation of two automatic devices for self-measurement of blood pressure according to the International Protocol of the European Society of Hypertension: The Omron M6 (HEM-7001-E) and the Omron R7 (HEM 637-IT)Blood Press. Monit.2006;11:165-171.
28. Zou KH, O'malley AJ, Mauri L. Receiver-operating characteristic analysis for evaluating diagnostic tests and predictive models. Circulation. 2007;115(5): 654-657.
29. Fluss R, Faraggi D, Reiser B. Estimation of the Youden Index and its associated cutoff point. Biom J. 2005;47(4):458-472.
30. Zhang Y, Ma C, Yang L, Bovet P, Xi Bo. Performance of modified blood pressure-to-height ratio for identifying hypertension in Chinese and American children. J Hum Hypertens. 2018;32(6):408-414.
31. Yazdi M, Assadi F, Daniali SS, Heshmat R, Mehrkash M, Motlagh ME, Qorbani M, Kelishadi RPerformance of modified blood pressure-toheight ratio for diagnosis of hypertension in children: The CASPIAN-V study. J Clin Hypertens (Greenwich). 2020;22(5):867-875.
32. Mourato FA, Mourato MF, Mattos SDaS, De Lima Filho JL, De Araújo Gueiros Lira GV, Nadruz W. New modifications of the blood pressure-to-height ratio for the diagnosis of high blood pressure in children. $J$ Clin Hypertens (Greenwich). 2018;20(2):413-415.
33. Koebnick C, Black MH, Wu J, Martinez MP, Smith N, Kuizon B, Cuan D, Young DR, Lawrence JM, Jacobsen SJHigh blood pressure in over weight and obese youth: implications for screening. J Clin Hypertens (Greenwich). 2013;15(11):793-805.
34. Swartz SJ, Srivaths PR, Croix B, Feig DI. Cost-effectiveness of ambulatory blood pressure monitoring in the initial evaluation of hyperten sion in children. Pediatrics. 2008;122(6):1177-1181.
35. Briasoulis A, Androulakis E, Palla M, Papageorgiou N, Tousoulis D. Whitecoat hypertension and cardiovascular events: a meta-analysis. J Hypertens. 2016;34(4):593-599
36. Foti KE, Appel LJ, Matsushita K, Coresh J, Alexander GC, Selvin E. Digit Preference in Office Blood Pressure Measurements, United States 2015-2019. Am J Hypertens. 2021;34(5):521-530.

## SUPPORTING INFORMATION

Additional supporting information may be found in the online version of the article at the publisher's website.

How to cite this article: Pérez-Gimeno G, Ruperez AI, Gil-Campos M, et al. Height-based equations as screening tools for high blood pressure in pediatric practice, the GENOBOX study. J Clin Hypertens. 2022;24:713-722.
https://doi.org/10.1111/jch. 14489


[^0]:    This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
    © 2022 The Authors. The Journal of Clinical Hypertension published by Wiley Periodicals LLC.

